Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase NA 3Phase 1 3Phase 3 2Phase 1/2 2Phase EARLY_PHASE1 1Phase 4 1

Status

Recruiting 3Terminated 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Dermatologic 5

Conditions

Melanoma 106Carcinoma, Non-Small-Cell Lung 34Carcinoma, Renal Cell 23Prostatic Neoplasms 17Neoplasms 15Brain Neoplasms 15Neoplasm Metastasis 14Lung Neoplasms 12Breast Neoplasms 11Uveal Melanoma 10Pancreatic Neoplasms 10Sarcoma 9Small Cell Lung Carcinoma 7Urinary Bladder Neoplasms 6Squamous Cell Carcinoma of Head and Neck 6Kidney Neoplasms 6Diabetes Mellitus, Insulin-Dependent, 12 6Carcinoma, Transitional Cell 6Carcinoma, Hepatocellular 6Skin Neoplasms 5Ovarian Neoplasms 5Histiocytoma, Malignant Fibrous 5Colorectal Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 4Recurrence 4Neuroendocrine Tumors 4Mesothelioma 4Glioblastoma 4Colonic Neoplasms 4

Interventions

aldesleukin 16Cyclophosphamide 14fludarabine phosphate 11Interleukin-2 11fludarabine 10Nivolumab 7pembrolizumab 5cemiplimab 5Ipilimumab 5Temozolomide 4Fluorouracil 4Aminolevulinic Acid 4sonidegib 3Surgical Procedures, Operative 3Radiotherapy 3zanolimumab 2trametinib 2talabostat 2montanide ISA 51 2dabrafenib 2Whole-Body Irradiation 2Tablets 2Semaxinib 2Radiation 2Petrolatum 2Peptides 2MART-1 Antigen 2Gefitinib 2Eflornithine 2Cisplatin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Skin Neoplasms × Ipilimumab × Clear all
NCT05779423 2026-05-19

Cryoablation+Ipilimumab+Nivolumab in Melanoma

Massachusetts General Hospital

Phase 2 Recruiting
37 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT04562129 2026-04-01

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
29 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT03071406 2026-03-11

Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Active not recruiting
50 enrolled 12 charts
Dermatologic

Neoplasm Metastasis, Skin Neoplasms, Carcinoma, Merkel Cell

NCT05926960 2026-03-09

PORTSIDE

Pfizer

Phase 2 Terminated
38 enrolled
Dermatologic

Melanoma, Skin Neoplasms

NCT04996823 2025-12-04

Axitinib + Ipilimumab in Advanced Melanoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Recruiting
25 enrolled
Dermatologic

Melanoma, Skin Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡